HIV replication inhibiting purine derivatives

US8026245B2 · kind B2 · utility

Assignee

• Janssen Pharmaceutica NA · BE

Inventors

• Paul Adriaan Jan Janssen · Vosselaar, BE
• Paulus Joannes Lewi · Turnhout, BE
• Marc René de Jonge · Tilburg, NL
• Lucien Maria Henricus Koymans · Retie, BE
• Frederik Frans Desiré Daeyaert · Beerse, BE
• Jan Heeres · Vosselaar, BE
• Hendrik Maarten Vinkers · Ekeren, BE
• Ruben Gerardus George Leenders · Nijmegen, NL
• Dirk Alfons Leo Vandenput

Key dates

• Filing date: Sep 21, 2004
• Grant date: Sep 27, 2011
• Expiry date: Apr 2, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D473/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of HIV infection wherein the compound of formula (I) is a compound of formulaa N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein A and B each represents a radical of formulaand wherein —C-D- represents a bivalent radical of formula—N═CH—NR17—  (c-1); or—NR17—CH═N—  (c-2);provided that when A represents a radical of formula (a) then B represents a radical of formula (b) and when A represents a radical of formula (b) then B represents a radical of formula (a).